Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 2/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.36 |
| ▸ | CTSS | P25774 | 9/20 | 0.36 |
| ▸ | PLK1 | P53350 | 4/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6794518 | 0.99 | PLK1 (0.36) | PRMT5WDR77CTSSPLK1ABCB1 | |
| SCHEMBL6787013 | 0.91 | PRMT5 (0.38) | PRMT5WDR77CTSSPLK1ABCB1 | |
| Lithium Ion SCHEMBL6800533 | 0.90 | PRMT5 (0.35) | PRMT5WDR77CTSSABCB1AURKA | |
| Lithium Ion SCHEMBL6794513 | 0.89 | PRMT5 (0.35) | PRMT5WDR77CTSSABCB1AURKA | |
| Hydrochloric Acid SCHEMBL6794118 | 0.89 | CTSS (0.38) | PRMT5WDR77CTSSRAD52 | |
| SCHEMBL6793863 | 0.88 | CTSS (0.38) | PRMT5WDR77CTSS | |
| SCHEMBL6792094 | 0.86 | PRMT5 (0.38) | PRMT5WDR77CTSS | |
| SCHEMBL6792457 | 0.84 | AGER (0.36) | — | |
| SCHEMBL6793583 | 0.84 | CARM1 (0.37) | PRMT5WDR77 | |
| Trifluoroacetic Acid SCHEMBL6794707 | 0.84 | CTSS (0.37) | CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | PRMT5 1416/4885WDR77 2717/4885CTSS 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.